Law360, New York (June 2, 2008, 12:00 AM EDT) -- Just weeks after Bayer AG yanked the leftover stock of its blood-clotting drug Trasylol from the U.S. market, a newly published study has revealed that patients receiving the drug have a greatly increased risk of death.
The final results of the long-awaited study, published last Thursday in the New England Journal of Medicine, showed that Trasylol increases the risk of death by 54% while also greatly increasing the risk of other heart complications.
Bayer suspended sales of Trasylol in November at the urging of the U.S....
Bayer's Trasylol Increases Risk Of Death: Study
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
